F
Freedom Biosciences
Pioneering biotechnology platform developing next-gen psychedelic therapeutics for depression and addiction
About Freedom Biosciences
Freedom Biosciences is a biotechnology startup that specializes in the development of next-generation neuropsychiatric therapeutics. The company is led by a team of experts in the fields of science and business, including Dr. John Krystal, a pioneering researcher in psychiatry, and Dina Burkitbayeva, co-founder of PsyMed Ventures.
Read full description
The company's primary focus is on creating a new class of antidepressants, with a particular emphasis on ketamine-based and neuropsychiatric pharmaceuticals. These are designed to provide more effective treatment options for people suffering from severe mental health disorders. The company's work is driven by the recognition of the need for novel treatment options, as witnessed by Dr. Krystal in his work with military veterans and those living with severe mental health and substance use disorders.
Freedom Biosciences operates in the biotechnology and pharmaceutical industry, serving clients who are in need of effective treatments for mental health disorders. The company's business model revolves around the research, development, and commercialization of innovative neuropsychiatric therapeutics.
The company generates revenue through the development and sale of these therapeutics. It is currently working on a pipeline of innovative clinical and preclinical stage programs, including therapies for treatment-resistant depression and comorbid major depressive disorder & substance use disorder.
In summary, Freedom Biosciences is a biotech startup that is developing innovative neuropsychiatric therapeutics to provide more effective treatment options for people suffering from severe mental health disorders.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Francisco, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 87.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Medical & Healthcare, Neurology, Mental Health, Non-Invasive medical devices and treatments
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Freedom Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAMOther financing | Feb 2025 | $0 | — | One Mind Accelerator | ↗ |
| EARLY VCOther financing | Feb 2023 | $0 | — | LongeVC | ↗ |
Growth signals
Latest recorded traffic for Freedom Biosciences is 1.7K monthly website visits, up 13.3% over the last three months. Freedom Biosciences's team grew 57.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
MBX Capital
Village Global
PsyMed Ventures
Startup Yale
Series A1 investor entered at this stage
LongeVC
Other known investors8 additional known investors
One Mind Accelerator
Beni VC
Focalpoint Ventures
Iter Investments
Manta Ray Ventures
UCEA Capital Partners
Unruly Capital
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Freedom Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Freedom Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.